ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 01/03/24

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten registered offering of 15,790,000 shares of its common stock, par value $0.001 per share (“Common Stock”), offered at a price of $28.50 per share, before underwriting discounts. The offerin...

2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for complement mediate...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the upcoming 42 nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at 8:15 a.m. PT. A webcast of the presentation may be accessed on the Events and Presentations page under t...

2023-12-07 12:26:16 ET Summary Arrowhead Pharmaceuticals is transitioning from a pre-commercialization phase to a fully commercial pharmaceutical company. The company is focused on bringing candidate drugs in varied disease categories to regulatory approval. Arrowhead is incre...

2023-12-04 04:30:00 ET Summary After five consecutive up weeks, we are now just 4.2% below the record-high water mark, set back in January 2022. The best performer last week was Blockchain, as Bitcoin and other cryptocurrencies continued to rally. Palladium prices fell last we...

2023-12-01 09:00:08 ET Summary Shares of Arrowhead Pharmaceuticals dropped this week after the company reported fiscal Q3 2023 results. Balance sheet concerns are weighing on the stock, and this is an urgent issue the company needs to address, and it has several options at its dis...

2023-11-29 20:27:04 ET Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2023 Earnings Conference Call November 29, 2023 4:30 PM ET Company Participants Vince Anzalone - Vice President, Investor Relations Chris Anzalone - President & Chief Executive Officer Javier Sa...

2023-11-29 16:04:27 ET More on Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals: A High-Risk, High-Reward Bet Arrowhead Pharmaceuticals Q4 2023 Earnings Preview GSK inks $1B deal to obtain rights to hepatitis B drug from J&J Seeking Alpha’s Quan...

- Conference Call and Webcast Today, November 29, 2023, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2023. The company is hosting a conference call today, November 29, 2023, at 4:30 p.m. ET to disc...